Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Anti-CD20 antibody
DRUG
3 trials
Sponsors
The University of Hong Kong
, Sanofi
, Heinrich-Heine University, Duesseldorf
Conditions
Hepatitis B
Immune Suppression
Liver Dysfunction
Relapsing-remitting Multiple Sclerosis
Thrombotic Thrombocytopenic Purpura
Phase 3
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Completed
NCT05468320
Sanofi
Thrombotic Thrombocytopenic Purpura
Start: 2022-11-21
End: 2024-12-26
Updated: 2025-12-30
Unknown Phase
Optimizing HBV Management During Anti-CD20 Antibodies
Completed
NCT03155984
The University of Hong Kong
Hepatitis B, Immune Suppression, Liver Dysfunction
Start: 2013-10-01
End: 2017-12-01
Updated: 2018-05-04
Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
Recruiting
NCT06586177
Heinrich-Heine University, Duesseldorf
Relapsing-remitting Multiple Sclerosis
Start: 2021-10-27
End: 2028-12-31
Target: 100
Updated: 2025-09-18
Related Papers
Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura.
2025-12-01
A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Hematology Transfusion and Cell Therapy
2023-10-01
A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura
Blood
2022-11-15